Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.
Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She is the founder and chief innovation officer of Opthea, a late-stage biopharmaceutical company developing a novel therapy to address the unmet need to treat retinal eye diseases.
Dr Baldwin's experience includes 10 years as the CEO and managing director of Opthea, where the company’s lead asset was advanced through preclinical studies to global Phase 3 registrational trials.
Dr Baldwin also has extensive capital raising experience, including the completion of a $180 million initial public offering and listing on the US Nasdaq exchange. Prior to Opthea, Dr Baldwin was employed at Genentech as a researcher before moving to its commercial division.
Dr Baldwin’s experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech’s early-stage oncology programs.
Race’s executive chair, Dr Pete Smith, said, “We are delighted to welcome Dr Megan Baldwin to our board as an Independent Non-Executive Director. She brings to the role an exceptional depth of experience in biotechnology and therapeutic drug development. Megan’s leadership at Opthea, steering the company through its global Phase 3 trials, reflects her visionary approach to addressing critical unmet medical needs. We look forward to leveraging her expertise and insights to help drive the future success of Race."
